Pangaea Oncology is a leading medical services company based in Barcelona, Spain. Established in 2007, our primary focus is precision oncology and personalized medicine, utilizing genetic analyses to enhance the survival rates and quality of life for cancer patients. Our mission is to revolutionize therapeutic oncology by implementing personalized models into standard medical practices.

We operate in two key areas. Firstly, our clinical care division, the Dr. Rosell Oncology Institute (IOR), delivers personalized medical oncology services and related activities across four major hospitals in Catalonia.

Secondly, our Diagnostic and R&D services division offers diagnostic and in-vitro services to both IOR patients and our portfolio of pharmaceutical clients, including multinational companies. At Pangaea, we are heavily invested in technology, particularly the development of innovative diagnostic techniques such as Liquid Biopsy. We have also partnered with Cancer Research Technology, UK, to advance targeted drug development through early clinical trial stages.

Our seasoned team of experts, led by Dr Rafael Rosell and Dr Santiago Ramon y Cajal, combines clinical and research experience to drive advancements in biomarker discovery, drug development, and diagnostic tools. Pangaea Oncology is committed to improving outcomes for cancer patients through personalized medicine and cutting-edge research